Interferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancer - The Cochrane Library - Lawal - Wiley Online Library

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the effectiveness and safety of interferon after surgery in the treatment of advanced (stage II-IV) epithelial ovarian cancer.

FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma -- The Oncologist

*the Oncologist now requires a subscription $$/abstracts available for free

Patient Safety:  note the adverse effects
"In the reviewed trial, serious adverse events and National Cancer Institute Common Terminology Criteria for Adverse Events grade 3 adverse events were reported more frequently in bevacizumab-treated patients (31% versus 19% and 63% versus 47%, respectively). The most common bevacizumab-related toxicities were bleeding/hemorrhage, hypertension, proteinuria, and venous or arterial thromboembolic events."